Postpartum Treatment for Substance Use Disorder Among Mothers of Infants with Neonatal Abstinence Syndrome and Prenatal Substance Exposure - Among Medicaid-insured women whose infants had in utero substance exposure, 15% received any postpartum SUD treatment. Fewer than half were diagnosed with SUD prenatally. Of those who received post- partum SUD treatment, 68% had received prenatal treatment. No association was observed between postpartum SUD treatment receipt and months of Medicaid enrollment in the year before delivery, prenatal visits, or post- partum visit attendance. Most women who likely need postpartum SUD treatment did not receive it and multipronged so- lutions are needed. These findings provide a useful baseline for evaluations of policies aimed at improving ma- ternal health.
The Lived Experience of Postpartum Women Attending Outpatient Substance Treatment for Opioid or Heroin Use - Five themes emerged from the raw data: the presence of a stigma in providers of health care services, a fear of being reported to family services, children are primary motivators to remain engaged in treatment, concern for the welfare of the infant, and barriers to treatment. Postpartum women with OUD and their infants have complex needs that may best be served by treatment programs that offer comprehensive care. The fear of being reported to family services and possible loss of custody influenced all aspects of their decision-making.
Presentation slides - Opioid and other substance use disorders during pregnancy (AHEC Grand Rounds)
